Efficacy and Safety of Different Doses of Bevacizumab Combined with Atezolizumab in Unresectable Hepatocellular Carcinoma.

Purpose: To evaluate the efficacy and safety of different doses of bevacizumab combined with atezolizumab in patients with unresectable hepatocellular carcinoma.

Methods: A retrospective analysis was conducted on clinical data from patients receiving Atezo-Bev therapy at our institution. Patients were stratified into standard-dose (SD) and low-dose (LD) groups based on bevacizumab dosage. Comparative analyses evaluated antitumor efficacy and adverse events (AEs) incidence.

Results: A total of 63 patients were included (SD group: n=32; LD group: n=31). Baseline characteristics showed no significant differences between the groups. Median overall survival (OS) was 22.0 months in the SD group and 19.3 months in the LD group, while median progression-free survival (PFS) was 8.0 months and 6.9 months, respectively. No statistically significant differences were observed in OS or PFS between the two groups (P=0.276 and P=0.297, respectively). However, the incidence of bevacizumab-related AEs was lower in the LD group compared to the SD group.

Conclusion: Compared to low-dose bevacizumab combined with atezolizumab, the standard-dose regimen did not demonstrate significant superiority in OS or PFS. Additionally, the low-dose combination may lead to fewer AEs.